Remibrutinib's Phase III Win Is Real, But the Disability Endpoint Language Is the Tell

Novartis's Remibrutinib Shows Superiority in Phase III RMS Trials

Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials for remibrutinib in relapsing multiple sclerosis (RMS). Remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority over teriflunomide in significantly reducing annualized relapse rate (ARR) and inflammatory brain lesions. The trials also showed clinically meaningful reductions in disability progression, with a positive trend in 3-month confirmed disability progression (3mCDP) and nominal significance in 6-month confirmed disability progression (6mCDP) in a combined analysis. The drug maintained a favorable safety profile, consistent with its broader development program, notably with no liver safety signal. Novartis plans to present these late-breaking data at MSToronto2026 and seek global regulatory approval.

• The REMODEL-1/-2 trials met their primary endpoint, demonstrating that remibrutinib significantly reduced the annualized relapse rate (ARR) compared to teriflunomide in adults with relapsing multiple sclerosis (RMS). Furthermore, the trials showed superiority of remibrutinib over teriflunomide on all key secondary endpoints within each trial, including a significant reduction in inflammatory brain lesions as measured by MRI, underscoring the drug's robust impact on disease activity.
• Remibrutinib achieved a clinically meaningful delay in disability progression, a critical outcome for patients with multiple sclerosis. A preplanned combined analysis of the REMODEL-1/-2 trials revealed a positive trend in 3-month confirmed disability progression (3mCDP) and nominally significant 6-month confirmed disability progression (6mCDP), indicating a potential benefit in slowing the long-term worsening of disability in the RMS patient population.
• The oral BTK inhibitor remibrutinib demonstrated a favorable safety profile across both Phase III trials, consistent with its extensive development program involving over 4,500 clinical trial participants in multiple indications. Importantly, the trials reported no liver safety signal, including no cases meeting Hy’s Law criteria, which addresses a key concern often associated with some oral therapies and highlights a differentiated benefit-risk profile.

Remibrutinib Delivers Robust Efficacy and Favorable Safety in RMS

Three recent studies offer meaningful insights into the efficacy and safety of disease-modifying therapies in relapsing multiple sclerosis.

The FREEDOMS extension trial evaluated long-term fingolimod treatment in patients with relapsing-remitting multiple sclerosis (RRMS). Patients in the continuous-fingolimod groups demonstrated a lower annualized relapse rate (p < 0.0001), reduced brain volume loss (p < 0.05), and a proportionately higher rate of freedom from 3-month confirmed disability progression (p < 0.05) compared with patients who had been on placebo. Within the placebo-fingolimod groups, annualized relapse rate was lower (p < 0.001, both) and brain volume loss was reduced after switching (p < 0.01, placebo-fingolimod 0.5 mg). Rates and types of adverse events were similar across groups, and no new safety issues were reported. The study provided Class IV evidence that long-term fingolimod treatment is well-tolerated and reduces relapse rates, disability progression, and MRI effects in patients with RRMS.

A pooled post hoc analysis of the FREEDOMS/FREEDOMS II trials examined the long-term effects of fingolimod 0.5 mg in young adult patients with RRMS aged ≤ 30 years, followed for up to 8 years (96 months). From month 0 to month 96, a significantly higher proportion of patients in the immediate treatment group achieved 6-month confirmed disability improvement (58.2% vs. 30.5%, p = 0.0206) and 6-month confirmed disability improvement-plus (70.6% vs. 42.3%, p = 0.0149), while significantly fewer reached 6-month confirmed disability progression (20.1% vs. 34.7%, p = 0.0058) or an Expanded Disability Status Scale score ≥ 4 (24.1% vs. 34.1%, p = 0.0041). Annualized relapse rates up to month 96 were lower in the immediate versus delayed group (0.16 vs. 0.38, p < 0.0001), and a higher proportion of patients in the immediate group were free of new/newly enlarging T2 lesions at month 48 (31.0% vs. 5.0%, p = 0.0011).

A network meta-analysis of adverse effects of immunotherapies for multiple sclerosis, encompassing 123 trials with 57,682 participants, assessed the relative safety of multiple agents including fingolimod, ocrelizumab, ozanimod, natalizumab, and others. Low-certainty evidence suggested that fingolimod met the non-inferiority criterion versus placebo for serious adverse events (relative risk 1.05, 95% CI 0.92 to 1.20), though low-certainty evidence indicated it may have increased withdrawals due to adverse events compared with placebo (relative risk 1.79, 95% CI 1.40 to 2.28). For ocrelizumab, low-certainty evidence suggested it met non-inferiority versus placebo for serious adverse events (relative risk 0.85, 95% CI 0.67 to 1.07). The analysis concluded that there is mostly low and very low-certainty evidence that drugs used to treat MS may not increase serious adverse events, but may increase withdrawals compared with placebo.

Unpacking the REMODEL-1/-2 Trial Design and Endpoints

Across the relapsing multiple sclerosis (RMS) therapeutic landscape, clinical trials have employed a range of designs — from randomized double-blind controlled trials to open-label assessor-masked studies — with endpoints spanning annualized relapse rate (ARR), MRI-based lesion metrics, disability progression, and patient-reported outcomes. The trials below represent key studies identified in the RMS literature, covering phase II through phase IV designs across multiple drug classes.

Beyond RMS: Remibrutinib's Expanding Therapeutic Horizon

Remibrutinib is being investigated across several immune-mediated and autoallergic indications beyond relapsing multiple sclerosis, reflecting the broad relevance of BTK inhibition in B cell- and myeloid cell-driven pathology. The clinical programme spans dermatological and systemic autoimmune conditions, with intervention models ranging from dose-finding phase 2b studies to large randomised phase 3 trials.

• Chronic Spontaneous Urticaria (CSU) — Phase 2b dose-finding: A randomised, double-blind, placebo-controlled trial evaluated remibrutinib at seven dose levels (10 mg once daily, 35 mg once daily, 100 mg once daily, 10 mg twice daily, 25 mg twice daily, 100 mg twice daily, or placebo) in a 1:1:1:1:1:1:1 ratio over 12 weeks in patients inadequately controlled with second-generation H-antihistamines (NCT03926611). The primary endpoints were weekly Urticaria Activity Score change from baseline at week 4 and safety.

• Chronic Spontaneous Urticaria (CSU) — Phase 3 (REMIX-1 and REMIX-2): Two randomised, placebo-controlled studies (NCT05030311; NCT05032157) randomised patients 2:1 to oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks). The primary endpoint was change from baseline in weekly Urticaria Activity Score at week 12.

• Chronic Spontaneous Urticaria (CSU) — Phase 3b (RECLAIM, NCT06868212): A US-based, multicenter, randomised, double-blind, double-dummy study will randomise approximately 400 patients 1:1 to oral remibrutinib (25 mg twice daily) or subcutaneous dupilumab (600 mg loading dose; 300 mg every 2 weeks), in addition to second-generation H-antihistamines, over a 12-week core treatment period. The primary endpoint is absolute change from baseline in weekly Urticaria Activity Score at week 4.

• Sjögren's Syndrome: Remibrutinib has been identified as being in phase 2 clinical trials for Sjögren's syndrome, reflecting its potential in systemic autoimmune conditions driven by B cell and Fc receptor signalling.

• Other immune-mediated dermatological conditions: BTK inhibitors, including remibrutinib, are noted as being explored in conditions such as pemphigus, hidradenitis suppurativa, systemic lupus erythematosus, and atopic dermatitis; however, The knowledge base does not have sufficient information on this aspect.

Remibrutinib's Pivotal Data: Reshaping the Oral MS Treatment Landscape

The positive topline results from Novartis' Phase III REMODEL-1/-2 trials for remibrutinib in relapsing multiple sclerosis (RMS) mark a significant moment for the MS treatment landscape. Demonstrating superiority over teriflunomide, an established oral disease-modifying therapy (DMT), in reducing annualized relapse rate (ARR) and inflammatory brain lesions is a substantial achievement. This positions remibrutinib as a formidable contender, potentially offering a new standard for oral treatment in RMS.

Beyond relapse reduction, the trials also reported clinically meaningful reductions in disability progression, with nominal significance in 6-month confirmed disability progression (6mCDP) in a combined analysis. This is a critical differentiator, as existing evidence indicates that many current DMTs have limited impact on progressive disability. The ability of remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, to address this unmet need is likely linked to its dual mechanism of action, inhibiting both pathogenic B cell autoreactivity and direct anti-inflammatory effects in microglia, thereby targeting both peripheral and central nervous system (CNS) inflammation.

Furthermore, the favorable safety profile, notably the absence of a liver safety signal, is a key competitive advantage. While other BTK inhibitors have faced varied safety profiles, this clean signal for remibrutinib could accelerate its adoption and provide reassurance to clinicians and patients. However, the MS market remains highly competitive, with numerous DMTs and other BTK inhibitors in advanced development. The long-term safety profile, particularly regarding any class-specific adverse events like bleeding risks seen with some BTKi, will be under close scrutiny. While promising for RMS, the broader impact on progressive MS forms, where CNS compartmentalized inflammation is paramount, will be a key area for future investigation and differentiation, especially given the heterogeneous outcomes observed with other BTKi in progressive MS trials. Ultimately, remibrutinib's data suggest it could become a significant oral treatment option, reshaping the treatment paradigm for RMS and potentially beyond.